CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 25,086 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00335452
NCT00335452Phase 3Completed

Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.

Sanofi·interventional·Posted Jun 9, 2006·Updated Nov 18, 2010

In Brief

A Phase 3 clinical trial evaluating Clopidogrel and acetylsalicyclic acid (ASA) for Acute Coronary Disease and Angina Unstable. Completed, enrolled 25,086 participants across 38 sites in 38 countries.

Detailed Summary

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 9, 2006
Enrollment StartJun 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.1 years ago

Interventions

Clopidogreldrug

oral administration

acetylsalicyclic acid (ASA)drug

oral administration